Aegerion Pharmaceuticals, Inc.  

(Public, NASDAQ:AEGR)   Watch this stock  
Find more results for AEGR
-0.24 (-1.27%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.51 - 19.08
52 week 17.73 - 36.68
Open 18.89
Vol / Avg. 345,824.00/565,583.00
Mkt cap 531.15M
P/E     -
Div/yield     -
EPS -1.37
Shares 28.57M
Beta 0.90
Inst. own 127%
Jul 27, 2015
Q2 2015 Aegerion Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 25, 2015
Aegerion Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 25, 2015
Aegerion Pharmaceuticals Inc Annual Shareholders Meeting
Jun 2, 2015
Aegerion Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 13, 2015
Aegerion Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Aegerion Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 4, 2015
Q1 2015 Aegerion Pharmaceuticals Inc Earnings Call - Webcast
May 4, 2015
Q1 2015 Aegerion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -26.65% -24.87%
Operating margin -15.46% -16.86%
EBITD margin - -16.09%
Return on average assets -14.83% -14.07%
Return on average equity -40.52% -28.82%
Employees 295 -
CDP Score - -


1 Main St Ste 800
CAMBRIDGE, MA 02142-1531
United States - Map
+1-617-5007867 (Phone)
+1-617-9457968 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company's products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein, which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA), as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Officers and directors

David I. Scheer Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Marc D. Beer Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
David Aubuchon Chief Accounting Officer
Bio & Compensation  - Reuters
Craig Fraser Chief Operating Officer,
Age: 50
Bio & Compensation  - Reuters
Anne Marie Cook Senior Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
William Andrews Senior Vice President - Business Development
Age: 50
Bio & Compensation  - Reuters
Martha Carter Senior Vice President, Chief Regulatory Officer
Age: 62
Bio & Compensation  - Reuters
Mark Sumeray M.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Mary Weger Chief Performance Officer
Age: 56
Bio & Compensation  - Reuters
Sol J. Barer Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters